BlueWind Medical raises $47.8m to advance commercialisation efforts for UUI treatment

BlueWind plans to use the funds for expanding sales functions and market access initiatives for its Revi implantable tibial neuromodulation system. BlueWind plans to use the funds for expanding sales functions and market access initiatives for its Revi implantable tibial neuromodulation system. Overactive bladder (OAB), or the frequent urge for an individual to empty their bladder, affects an estimated 33 million people in the US, with around half of those struggling with UUI, wherein bladder leakage occurs, according to the National Association for Continence (NAFC). Credit: Vector_Leart / Shutterstock.com BlueWind Medical has raised $47.8m to expand commercialisation of its implantable…

Source: Medical Device Network